RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Magenta Therapeutics Stock

Magenta Therapeutics ROA 2024

Magenta Therapeutics ROA

-0.52

Ticker

MGTA

ISIN

US55910K1088

WKN

A2JPD6

In 2024, Magenta Therapeutics's return on assets (ROA) was -0.52, a 39.22% increase from the -0.37 ROA in the previous year.

Magenta Therapeutics Aktienanalyse

What does Magenta Therapeutics do?

Magenta Therapeutics Inc is a groundbreaking biotechnology company specializing in the development of novel therapies for serious blood disorders. The company uses a unique technology platform based on stem cell transplantation and gene editing to develop innovative therapies that have the potential to improve the lives of millions of people worldwide. Magenta Therapeutics was founded in 2016 by an experienced team of executives and scientists who had previously worked in various biotech companies. The company is headquartered in Cambridge, Massachusetts, USA and has been listed on the NASDAQ stock exchange since 2018. Its business model is based on the development and commercialization of innovative therapies for blood diseases, based on a stem cell technology platform and gene editing technology. These technologies are intended to improve the treatment of blood diseases and enhance the quality of life for patients. Magenta Therapeutics has a comprehensive portfolio of therapy candidates targeting various aspects of stem cell transplantation and gene editing. These therapies aim to reduce the risks and burdens of traditional stem cell transplantation while fully harnessing the potential of stem cell transplantation to cure or alleviate blood diseases. The company has three major business areas: stem cell therapy, gene therapy, and cell therapy. In the context of these business areas, Magenta Therapeutics has already developed several therapy candidates that are currently in various stages of clinical development. The company's work is supported by a variety of financial investors, including some of the most respected names in the biotech industry. Magenta Therapeutics is also actively involved in developing partnerships with other leading companies in the biotechnology industry to further leverage the potential of its platform technology. In conclusion, Magenta Therapeutics is a young and innovative company focused on developing and commercializing new groundbreaking therapies for blood diseases. With its approach of combining stem cell technology and gene editing, the company has the potential to improve the lives of millions of patients with blood diseases while also achieving a significant return for its investors. Magenta Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Magenta Therapeutics's Return on Assets (ROA)

Magenta Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Magenta Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Magenta Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Magenta Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Magenta Therapeutics stock

What is the Return on Assets (ROA) of Magenta Therapeutics this year?

The Return on Assets (ROA) of Magenta Therapeutics is -0.52 undefined this year.

What was the ROA of Magenta Therapeutics compared to the previous year?

The ROA of Magenta Therapeutics has increased by 39.22% compared to the previous year.

What consequences do high ROA have for investors of Magenta Therapeutics?

A high ROA is advantageous for investors of Magenta Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Magenta Therapeutics?

A low ROA can be unfavorable for investors of Magenta Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Magenta Therapeutics affect the company?

An increase in ROA of Magenta Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Magenta Therapeutics impact the company?

A reduction in the ROA of Magenta Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Magenta Therapeutics?

Some factors that can influence the ROA of Magenta Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Magenta Therapeutics important for investors?

The ROA of Magenta Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Magenta Therapeutics take to improve ROA?

To improve ROA, Magenta Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Magenta Therapeutics pay?

Over the past 12 months, Magenta Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Magenta Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Magenta Therapeutics?

The current dividend yield of Magenta Therapeutics is .

When does Magenta Therapeutics pay dividends?

Magenta Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Magenta Therapeutics?

Magenta Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Magenta Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Magenta Therapeutics located?

Magenta Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Magenta Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Magenta Therapeutics from 10/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/27/2024.

When did Magenta Therapeutics pay the last dividend?

The last dividend was paid out on 10/27/2024.

What was the dividend of Magenta Therapeutics in the year 2023?

In the year 2023, Magenta Therapeutics distributed 0 USD as dividends.

In which currency does Magenta Therapeutics pay out the dividend?

The dividends of Magenta Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Magenta Therapeutics

Our stock analysis for Magenta Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Magenta Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.